Troy A. Ignelzi Purchases 9,900 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

Rapport Therapeutics (NASDAQ:RAPP) CFO Troy A. Ignelzi acquired 9,900 shares of the business’s stock in a transaction dated Wednesday, March 12th. The shares were acquired at an average cost of $10.10 per share, with a total value of $99,990.00. Following the transaction, the chief financial officer now owns 9,900 shares in the company, valued at approximately $99,990. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Rapport Therapeutics Stock Up 4.9 %

Shares of Rapport Therapeutics stock opened at $10.51 on Friday. The stock’s fifty day moving average is $13.54 and its 200 day moving average is $18.74. Rapport Therapeutics has a one year low of $6.43 and a one year high of $29.74.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in RAPP. Deutsche Bank AG purchased a new stake in Rapport Therapeutics in the 4th quarter worth approximately $41,000. Crestline Management LP purchased a new stake in shares of Rapport Therapeutics in the fourth quarter worth $488,000. Virtus ETF Advisers LLC bought a new stake in shares of Rapport Therapeutics during the 4th quarter valued at $66,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Rapport Therapeutics by 9.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,143,384 shares of the company’s stock valued at $20,285,000 after buying an additional 95,976 shares in the last quarter. Finally, TRV GP V LLC bought a new position in Rapport Therapeutics in the 4th quarter worth $126,579,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.